Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data

By Zacks Investment ResearchStock MarketsSep 23, 2021 09:00PM ET
www.investing.com/analysis/jj-etfs-to-gain-on-upbeat-covid19-vaccine-data-200602939
J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data
By Zacks Investment Research   |  Sep 23, 2021 09:00PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
AAPL
+2.56%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
XLV
+2.32%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Johnson & Johnson JNJ has again announced positive data highlighting the efficiency of its single-shot COVID-19 vaccine in providing protection against COVID-related hospitalizations. In this regard, Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson has reportedly said that “Our single-shot vaccine generates strong immune responses and long-lasting immune memory. And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases.”

According to Johnson & Johnson, the largest real-world evidence study for a COVID-19 vaccine highlighted stable vaccine effectiveness of 79% (CI, 77%-80%) for COVID-induced infections and 81% (CI, 79%-84%) for hospitalizations due to COVID-19. Moreover, there was no evidence suggesting any decline in the vaccine efficiency over the study period. The study involved 390,000 people who were administered the Johnson & Johnson single-shot COVID-19 vaccine against roughly 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity and conducted over the March to late July 2021 period (per the company).

Positive data was released with respect to the booster shot as well. Per the company, data from the Phase 3 ENSEMBLE 2 study demonstrated that another shot of the Johnson & Johnson COVID-19 vaccine administered 56 days after the first resulted in 100% protection (CI, 33-100%) against severe/critical COVID-19, at least 14 days after-final vaccination. The data also highlighted that 75% protection against symptomatic (moderate to severe/critical) COVID-19 worldwide (CI, 55-87%). Notably, 94% protection was observed against symptomatic (moderate to severe/critical) COVID-19 in the United States (CI, 58-100%).

ETFs That May Gain

Considering the important role played by coronavirus vaccines in Johnson & Johnson’s recent earnings results, the latest developments can be a positive for the stock. Notably, Johnson & Johnson’s single-dose COVID-19 vaccine, which was approved for emergency/conditional use in some countries this year, generated sales of $164 million in the second quarter compared with $100 million in the first quarter.

The company raised its guidance for 2021 earnings and sales to include a $2.5-billion contribution from its COVID-19 vaccine as well as expected growth in the base business. J&J expects more than half of the $2.5 billion in revenues from COVID-19 vaccines to come through in the fourth quarter.

The news has put the spotlight on a number of ETFs that could benefit the most due to their high exposure to J&J. Let’s take a look at these funds:

iShares U.S. Pharmaceuticals ETF IHE

This ETF provides exposure to 47 companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. Of these, Johnson and Johnson takes the top spot, accounting for about 22.6% share. The product charges 42 bps in fees (read: Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan).

iShares Evolved U.S. Innovative Healthcare ETF IEIH

This actively-managed ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector. Holding 249 stocks in its basket, J&J holds the second position with a 9.1% allocation. The product charges 18 bps in annual fees (read: Pharma & Healthcare ETFs at a One-Year High: Here's Why).

The Health Care Select Sector SPDR Fund XLV

The most-popular healthcare ETF, XLV follows the Health Care Select Sector Index. Expense ratio is 0.12%. In total, the fund holds 64 securities in its basket, with Johnson & Johnson taking the top spot, accounting for 8.7% of the assets (read: 5 ETFs to Combat Stimulus Tapering Concerns, Virus Woes).

iShares U.S. Healthcare ETF IYH

This fund offers exposure to 116 securities by tracking the Russell 1000 Health Care RIC 22.5/45 Capped Gross Index. Here again, Johnson & Johnson dominates the fund’s returns with 8.1% of the total assets. The product charges 41 bps in annual fees (read: Climb the "Wall of Worry" With These ETFs).

First Trust Nasdaq Pharmaceuticals ETF FTXH

This ETF tracks the Nasdaq US Smart Pharmaceuticals Index and holds 28 stocks in its basket. Of these, Johnson & Johnson occupies the second position with a 7.9% allocation. It charges 60 bps in annual fees.


More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.

Click here for the 4 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Health Care Select Sector SPDR ETF (NYSE:XLV): ETF Research Reports

iShares U.S. Healthcare ETF (IYH): ETF Research Reports

iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports

First Trust NASDAQ Pharmaceuticals ETF (FTXH): ETF Research Reports

iShares Evolved U.S. Innovative Healthcare ETF (IEIH): ETF Research Reports

To read this article on Zacks.com click here.

Zacks Investment Research
J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data
 

Related Articles

Vince Martin
Micron Looks Like A Buy, But Not Yet By Vince Martin - Oct 04, 2022 6

So far, the market has shrugged off last week’s disappointing outlook from Micron The long view makes some sense, as Micron is an intensely cyclical company One key question:...

J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email